Revenue decline and widening losses are the key negatives for a pre-commercial biotech. The $516.6M cash position provides a long runway, but the burn rate is accelerating. Watch for upcoming data readouts from GB-0895 Phase 3 and GB-4362 Phase 1 as potential catalysts. The IPO overhang may still be digesting given the recent March 2 pricing.
GENB drugs
GENB drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $13.59entry
- T+1 · 6mo ago +0.52%α −0.31% · $13.66
- T+5 · 6mo ago +19.35%α +17.85% · $16.22
- T+20 · 6mo ago −5.00%α −8.14% · $12.91
- T+60 · 4mo ago +5.52%α +1.69% · $14.34
Price Chart
How similar events traded
Executive Summary
Generate Biomedicines reported Q1 2026 collaboration revenue of $7.2M (down 18% YoY from $8.8M) and a net loss of $61.7M, wider than the $44.3M loss in Q1 2025. The company ended the quarter with $516.6M in cash after its March IPO, providing runway into H1 2028, but the widening loss and revenue decline are the headline financials for a pre-revenue biotech.
Key Financial Metrics
Key Facts
- Q1 2026 collaboration revenue $7.2M vs $8.8M in Q1 2025, an 18% YoY decline
- Net loss widened to $61.7M from $44.3M in the prior-year quarter
- Cash, cash equivalents, and marketable securities of $516.6M as of March 31, 2026, up from $221.5M at year-end 2025, reflecting $369.3M in net IPO proceeds
- Cash runway guided into first half of 2028; company expects to require additional capital for long-term operations
- R&D expenses rose to $57.8M from $46.8M, driven by Phase 3 investment in GB-0895 and personnel costs
- GB-0895 (anti-TSLP) Phase 3 trials SOLAIRIA-1 and SOLAIRIA-2 in severe asthma are advancing; Phase 1b in COPD ongoing
- GB-4362 (MMAE neutralizer) received FDA Fast Track designation; first patient dosing expected mid-2026
- GB-5267 (MUC16 armored CAR T) first patient dosing expected H2 2026 in Phase 1 solid tumor trial
Financial Impact
Revenue declined $1.6M YoY (18%); net loss increased $17.4M (39%); operating cash burn increased to $80.4M from $53.2M
Risk Factors
- No approved products or recurring revenue stream; entirely dependent on partnership collaboration revenue
- Accelerating cash burn ($80.4M operating cash outflow in Q1) may require future dilutive financing
- Phase 3 clinical trial risk for GB-0895; failure would remove the most advanced pipeline asset
- Competition from established anti-TSLP therapies (e.g., Tezspire) in severe asthma
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-209899 |
| Document: ck0002100782-20260507.htm | 0001193125-26-209899 |
| Document: 0001193125-26-209899-index-headers.html | 0001193125-26-209899 |
| Document: 0001193125-26-209899-index.html | 0001193125-26-209899 |
| Document: 0001193125-26-209899.txt | 0001193125-26-209899 |
| 8-K Data (Synthetic) | 0001193125-26-209899 |
Track record
11 reports on GENB
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +14.28% at T+20 after the Oct 1, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 5/10 Entry $12.57 Now $10.49 +16.55% settles Dec 11
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $12.57 Now $10.49 −16.55% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $13.85 Now $10.49 −24.26% settles Dec 2
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $14.46 Now $10.49 −27.46% settles Nov 30
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $12.52 to $13.49 Now $10.49 −16.21% ▲ +7.75% +9.02% vs SPY
- Oct 1, 20266w ago Press Release Bullish 5/10 Entry $13.80 to $15.77 Now $10.49 −23.99% ▲ +14.28% +13.57% vs SPY
- May 7, 202627w ago 8-K Bearish 6/10 Viewing Entry $13.59 to $12.91 Now $10.49 +22.81% ▲ +5.00% +8.14% vs SPY
- Mar 2, 202637w ago Insider Cluster Bullish 7/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
- Mar 2, 202637w ago Insider Cluster Neutral 3/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
- Feb 27, 202637w ago 424B4 Bearish 7/10 Entry $12.17 to $11.51 Now $10.49 +13.80% ▲ +5.42% −2.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers